/
Company Overview Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ( IBD ) and rheumatic diseases. Spyre s pipeline includes extended half-life antibodies targeting 4 7, TL1A, and IL-23 in development as monotherapies and pair-wise combinati…
$100.23
+$6.11 (+6.49%)
EOD Jul 17, 2026
Negative free cash flow of -$169M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$179M
▲ +25.4% YoY
Op. Margin
—
ROIC
-27.74%
▲ +20.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$186M
▼ -7.5% YoY
Op. Cash Flow (TTM)
-$186M
▼ -7.5% YoY
Net Debt
-$741M
Net Cash Position
Cash & Equiv.
$741M
Continue Research
Spyre Therapeutics (SYRE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Spyre Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Spyre Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -27.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SYRE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.